Optimizing the use of anthracyclines in older patients with breast cancer Journal Article
| Authors: | Morris, P. G.; Fornier, M. N. |
| Article Title: | Optimizing the use of anthracyclines in older patients with breast cancer |
| Abstract: | Recently, a greater understanding of tumor biology, including the use of genetic signatures, has led to a more precise classification of breast cancer. This has translated into a more granular assessment of risk-benefit calculations for the selection of patients for adjuvant therapies. For unselected patients, anthracyclines offer a survival benefit over non-anthracycline-based regimens, but are associated with long-term risks including congestive heart failure. Until recently, the benefit of anthracyclines in older patients with early breast cancer was largely extrapolated from studies involving younger cohorts. Emerging data now suggest that for appropriately selected older patients anthracyclines offer distinct benefits and are associated with a manageable toxicity profile. This review will focus on the benefits and risks of anthracyclines in older patients with various subtypes of breast cancer. © 2010 Elsevier Ireland Ltd. |
| Keywords: | protein expression; overall survival; fatigue; review; doxorubicin; fluorouracil; drug dose reduction; drug efficacy; drug safety; drug withdrawal; patient selection; risk benefit analysis; solid tumor; unspecified side effect; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; cancer adjuvant therapy; disease free survival; methotrexate; cancer incidence; medical decision making; multiple cycle treatment; breast cancer; bone marrow suppression; blood toxicity; epidermal growth factor receptor 2; cohort analysis; cyclophosphamide; docetaxel; febrile neutropenia; chemotherapy induced emesis; cardiotoxicity; tamoxifen; nausea and vomiting; epirubicin; age distribution; taxane derivative; cancer classification; anthracycline derivative; estrogen receptor; trastuzumab; drug dose increase; navelbine; anthracycline; anthracyclines; elderly care; congestive heart failure; drug indication; dose dense chemotherapy; older patients; risk-benefit analyses; drug choice |
| Journal Title: | Critical Reviews in Oncology/Hematology |
| Volume: | 77 |
| Issue: | 2 |
| ISSN: | 1040-8428 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2011-02-01 |
| Start Page: | 131 |
| End Page: | 141 |
| Language: | English |
| DOI: | 10.1016/j.critrevonc.2010.02.001 |
| PROVIDER: | scopus |
| PUBMED: | 20227291 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 4 March 2011" - "CODEN: CCRHE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work